CA2859773C - Contrast agent for imagining myocardial perfusion - Google Patents

Contrast agent for imagining myocardial perfusion Download PDF

Info

Publication number
CA2859773C
CA2859773C CA2859773A CA2859773A CA2859773C CA 2859773 C CA2859773 C CA 2859773C CA 2859773 A CA2859773 A CA 2859773A CA 2859773 A CA2859773 A CA 2859773A CA 2859773 C CA2859773 C CA 2859773C
Authority
CA
Canada
Prior art keywords
imaging
imaging agent
use according
patient
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2859773A
Other languages
English (en)
French (fr)
Other versions
CA2859773A1 (en
Inventor
Martin Johansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respiratorius AB
Original Assignee
Respiratorius AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respiratorius AB filed Critical Respiratorius AB
Publication of CA2859773A1 publication Critical patent/CA2859773A1/en
Application granted granted Critical
Publication of CA2859773C publication Critical patent/CA2859773C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2859773A 2011-12-22 2012-12-18 Contrast agent for imagining myocardial perfusion Active CA2859773C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579113P 2011-12-22 2011-12-22
SE1151249-8 2011-12-22
SE1151249 2011-12-22
US61/579,113 2011-12-22
PCT/SE2012/051421 WO2013095273A1 (en) 2011-12-22 2012-12-18 Contrast agent for imagining myocardial perfusion

Publications (2)

Publication Number Publication Date
CA2859773A1 CA2859773A1 (en) 2013-06-27
CA2859773C true CA2859773C (en) 2020-09-01

Family

ID=48668967

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2859773A Active CA2859773C (en) 2011-12-22 2012-12-18 Contrast agent for imagining myocardial perfusion

Country Status (15)

Country Link
US (2) US9295738B2 (https=)
EP (1) EP2793952B1 (https=)
JP (1) JP6140187B2 (https=)
KR (1) KR101931792B1 (https=)
CN (1) CN104114191A (https=)
AU (1) AU2012354223B2 (https=)
BR (1) BR112014015124A2 (https=)
CA (1) CA2859773C (https=)
ES (1) ES2687234T3 (https=)
IL (1) IL233219A (https=)
MX (1) MX356258B (https=)
RU (1) RU2629840C2 (https=)
SG (1) SG11201403429YA (https=)
WO (1) WO2013095273A1 (https=)
ZA (1) ZA201405199B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9955876B2 (en) * 2016-09-08 2018-05-01 Raul Chirife Device and method for assessment of left ventricular ejection fraction and other parameters of cardiac performance
CN107233585B (zh) * 2017-06-09 2021-01-22 四川大学华西医院 黄连素或其衍生物在制备心肌灌注显像剂中的用途
CN114832118B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 化合物i液体组合物、制备方法及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2005033079A1 (ja) 2003-09-30 2005-04-14 Eisai Co., Ltd. ヘテロ環化合物を含有する新規な抗真菌剤
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
WO2010097410A1 (en) * 2009-02-24 2010-09-02 Respiratorius Ab Novel bronchodilating diazaheteroaryls

Also Published As

Publication number Publication date
EP2793952B1 (en) 2018-06-13
US9687565B2 (en) 2017-06-27
CN104114191A (zh) 2014-10-22
HK1201459A1 (en) 2015-09-04
ZA201405199B (en) 2015-12-23
JP6140187B2 (ja) 2017-05-31
KR101931792B1 (ko) 2019-03-13
MX2014007491A (es) 2015-02-17
JP2015500873A (ja) 2015-01-08
BR112014015124A2 (pt) 2017-06-13
ES2687234T3 (es) 2018-10-24
CA2859773A1 (en) 2013-06-27
RU2014125849A (ru) 2016-02-10
AU2012354223B2 (en) 2017-03-16
RU2629840C2 (ru) 2017-09-04
MX356258B (es) 2018-05-16
IL233219A0 (en) 2014-08-31
EP2793952A1 (en) 2014-10-29
US20160101195A1 (en) 2016-04-14
IL233219A (en) 2016-08-31
AU2012354223A1 (en) 2014-07-03
US9295738B2 (en) 2016-03-29
SG11201403429YA (en) 2014-07-30
US20140341808A1 (en) 2014-11-20
EP2793952A4 (en) 2015-09-09
WO2013095273A1 (en) 2013-06-27
KR20140107411A (ko) 2014-09-04

Similar Documents

Publication Publication Date Title
CN106977429B (zh) 用于合成和使用造影剂的组合物、方法和系统
US10201625B2 (en) Radiolabelled octreotate analogues as PET tracers
CN102336741B (zh) 氟-18标记的心肌灌注显像剂及其制备方法和应用
JP6987840B2 (ja) Ｉｄｏ１酵素イメージングのための放射性リガンド
US9687565B2 (en) Diagnostic kit
JP2002525325A (ja) 放射標識化ニューロキニン−１受容体拮抗薬
USRE43688E1 (en) Compositions and methods related to serotonin 5-HT1A receptors
Olberg et al. Brain penetrant small molecule 18F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats
Nkepang et al. Facile synthesis of para-[18F] fluorohippurate via iodonium ylide-mediated radiofluorination for PET renography
HK1201459B (en) Contrast agent for imagining myocardial perfusion
CN113387896B (zh) 一种4-（2-氯芳基）喹唑啉-2-酰胺衍生物及其应用
WO2014184682A1 (en) Radiolabeled gnrh antagonists as pet imaging agents
KR101519006B1 (ko) 신규한 벤즈아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 피부암 진단용 약학적 조성물
US11065349B2 (en) 18F labeled BODIPY dye and its derivatives for PET imaging of heart perfusion and others
JP2014516343A (ja) 中枢神経系の疾患のイメージング、診断及び／又は治療に使用のための化合物
CN108066776A (zh) 快速成像的坏死心肌显像剂及其制备方法和应用
HK40042293A (en) Radioactive imidazothiadiazole derivative compound
HK1241356A1 (en) Compositions, methods and systems for the synthesis and use of imaging agents
JP2014218454A (ja) スチリルピリジン誘導体化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171027

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240731